Home › Trial NCT05025735
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
- Trial IDNCT05025735
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorSaint Luke's Health System
- Enrollment25
- Start date2021-08-25
- ConditionsMetastatic Breast Cancer · HER2-negative Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.